Heat Biologics (HTBX) Reports Positive Data from Phase 2 Trial Evaluating HS-410 (Vesigenurtacel-L) in Combination with Standard of Care BCG
Tweet Send to a Friend
100% of non-muscle invasive bladder cancer patients who generated an immune response to low dose HS-410 and also received standard ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
